美股详情

本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务

百济神州

262.41

-1.0100-0.38%

盘后：259.00-3.4100-1.30%19:05 EDT

成交量：28.26万

成交额：7,378.30万

市值：310.72亿

市盈率：-70.86

高：264.00

开：260.00

低：257.41

收：263.42

数据加载中...

总览公司新闻公告

头对头礼来“匹妥布替尼”！百济神州 BTK 降解剂又启动一项 Ⅲ 期临床

Insight数据库

遭高瓴资本减持百亿！百济神州净利润仍未扭亏

【研报掘金丨申万宏源研究：百济神州开始进入盈利拐点，维持”买入“评级】申万宏源研究指出，百济神州(688235.SH)2025年Q1实现收入80.48 亿元，同比+50.2%，产品收入为79.85亿元，同比+49.9%，实现归母净利润-0.95 亿元，上年同期为-19.08亿元，亏损大幅收窄，若按照美国公认会计原则（GAAP），公司首次实现季度盈利，业绩符合预期。产品收入的增长主要得益于自研产品泽布替尼,以及替雷利珠单抗和安进授权产品的销售增长。根据公司公告，百济神州2025 年全年总收入指引仍为49 亿至53 亿美元，强劲增长的预期受益于泽布替尼在美国的领先地位以及在欧洲和全球其他重要市场的持续扩张。公司是市场上稀缺的同时具有全球化研发和销售能力的创新药公司，核心产品持续放量，公司开始进入盈利拐点，维持”买入“评级。

百济神州午前涨逾3% 首季度业绩符合市场预期

港股异动 | 百济神州(06160)午前涨超3% 首季度业绩符合市场预期主要产品在美市场份额持续提升

百济神州启动BGB-16673 vs Pirtobrutinib头对头III期研究

港股生物医药股走高百济神州减亏诺诚健华首季盈利

百济神州2025财年第一财季实现净利润1.27百万美元，同比增加100.51%

高瓴不再是百济神州5%以上持股股东新“医药一哥”被减持背后：下一个重磅产品待寻

每日经济新闻

高瓴资本减持百济神州套现36.8亿美元转投恒瑞医药港股IPO

高瓴减持百济神州，业内人士：基金到期，LP有分配的需求，系正常退出

21世纪经济报道

高瓴减持百济神州，业内人士：基金到期，LP有分配的需求，系正常退出

高瓴减持百济神州，持股比例降至5%以下！业内人士：基金到期，LP有分配的需求，系正常退出

南方财经网

高瓴抛售百济神州套现至少37亿美元要去认购恒瑞医药新股

百济神州将在2025年欧洲血液学协会年会展示血液学产品组合新数据

百济神州5月14日成交额为5821.09万美元

中金：维持百济神州“跑赢行业”评级目标价198港元

中金：维持百济神州(06160)“跑赢行业”评级目标价198港元

百济神州2025年一季报简析：营收上升亏损收窄，盈利能力上升

高瓴减持！

中国基金报

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/hans/stock/ONC/news?page=4"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ONC","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ONC\",,,,,undefined,":{"symbol":"ONC","market":"US","secType":"STK","nameCN":"百济神州","latestPrice":262.41,"timestamp":1749672000000,"preClose":263.42,"halted":0,"volume":282617,"hourTrading":{"tag":"盘后","latestPrice":259,"preClose":262.41,"latestTime":"19:05 EDT","volume":726,"amount":190220.4216,"timestamp":1749683102613},"delay":0,"floatShares":75624000,"shares":118408800,"eps":-3.70325,"marketStatus":"盘后交易","change":-1.01,"latestTime":"06-11 19:51:09 EDT","open":260,"high":264,"low":257.41,"amount":73783012.36955999,"amplitude":0.025017,"askPrice":263,"askSize":8,"bidPrice":257,"bidSize":15,"shortable":3,"etf":0,"ttmEps":-3.70325,"tradingStatus":3,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1749686400000},"marketStatusCode":4,"adr":0,"adrRate":13,"exchange":"NASDAQ","adjPreClose":263.42,"preHourTrading":{"tag":"盘前","latestPrice":263.42,"preClose":263.42,"latestTime":"09:25 EDT","volume":1013,"amount":266845.34131,"timestamp":1749648300018},"postHourTrading":{"tag":"盘后","latestPrice":259,"preClose":262.41,"latestTime":"19:05 EDT","volume":726,"amount":190220.4216,"timestamp":1749683102613},"volumeRatio":0.809026,"impliedVol":0.4254,"impliedVolPercentile":0.4455},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ONC\",,,,,undefined,":{"symbol":"ONC","floatShares":75624000,"roa":"-3.22%","roe":"-11.44%","lyrEps":-6.124009,"volumeRatio":0.809026,"shares":118408800,"dividePrice":0,"high":264,"amplitude":0.025017,"preClose":263.42,"low":257.41,"week52Low":141.31,"pbRate":"8.88","psRate":"7.44","week52High":287.88,"institutionHeld":0,"latestPrice":262.41,"committee":0.304348,"eps":-3.70325,"divideRate":0,"volume":282617,"delay":0,"ttmEps":-3.70325,"open":260,"prevYearClose":184.71,"prevWeekClose":255.86,"prevMonthClose":245.58,"prevQuarterClose":272.17,"fiveDayClose":258.27,"twentyDayClose":224.73,"sixtyDayClose":265.07},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ONC\",pageSize:20,pageCount:4,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2535319879","title":"头对头礼来“匹妥布替尼”！百济神州 BTK 降解剂又启动一项 Ⅲ 期临床","url":"https://stock-news.laohu8.com/highlight/detail?id=2535319879","media":"Insight数据库","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535319879?lang=zh_cn&edition=fundamental","pubTime":"2025-05-16 15:43","pubTimestamp":1747381431,"startTime":"0","endTime":"0","summary":"5 月 15 日，Clinicaltrials.gov 网站显示，百济神州启动一项 BTK 降解剂 BGB-16673 的 Ⅲ 期临床，旨在评估BGB-16673与匹妥布替尼在复发/难治性慢性淋巴细胞白血病或小淋巴细胞淋巴瘤成人患者中的安全性和有效性。截至 2024 年 5 月 24 日，共有 49 名 CLL 患者入组并接受治疗。其中200 mg 剂量组的ORR 为 94%，包括 2 例 CR。首次缓解的中位时间为 2.8 个月。17 名患者持续治疗≥ 9 个月，所有 17 名患者均持续缓解。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250516221642a481040c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250516221642a481040c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0708995401.HKD","LU1366192091.USD","LU1974910355.USD","ONC","SG9999014880.SGD","LLY","LU2746668461.USD","LU1983299246.USD","SGXZ57979304.SGD","LU1917777945.USD","LU2361044865.SGD","SG9999014906.USD","LU1989771016.USD","LU0289739699.SGD","SG9999015945.SGD","BK4588","SGXZ81514606.USD","IE00B2B36J28.USD","LU2491049909.HKD","LU2471134523.USD","LU1023059063.AUD","LU2324357040.USD","IE00BJJMRZ35.SGD","LU0320765992.SGD","LU0097036916.USD","LU2750360997.AUD","LU0114720955.EUR","LU0238689110.USD","LU2468319806.SGD","BK4534","LU0316494557.USD","LU0320765059.SGD","IE00B1BXHZ80.USD","LU1804176565.USD","LU0820561818.USD","LU2089984988.USD","LU0006306889.USD","LU2264538146.SGD","LU2471134879.HKD","SGXZ31699556.SGD","SG9999015986.USD","LU2237438978.USD","LU0079474960.USD","LU1720051017.SGD","LU2112291526.USD","LU2602419157.SGD","LU2552382132.HKD","LU2360106947.USD","LU2106854487.HKD","LU0417517546.SGD"],"gpt_icon":1},{"id":"2535355372","title":"遭高瓴资本减持百亿！百济神州净利润仍未扭亏","url":"https://stock-news.laohu8.com/highlight/detail?id=2535355372","media":"财中社","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535355372?lang=zh_cn&edition=fundamental","pubTime":"2025-05-16 14:34","pubTimestamp":1747377275,"startTime":"0","endTime":"0","summary":"被称为中国创新药“一哥”的百济神州（688235/06160/ONC），迎来重要股东减持。5月14日晚间，百济神州公告称，公司股东股东HHLRFund,L.P.及其联属实体于2025年5月9日减持公司境外流通股股份1600万股，持股比例从6.03%变更为4.89%，不再为公司持股5%以上股东。百济神州港股5月9日收盘价140.4港元。据此计算，本次减持金额22.46亿港元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202505163406715483.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["ONC","06160"],"gpt_icon":1},{"id":"2535300273","title":"【研报掘金丨申万宏源研究：百济神州开始进入盈利拐点，维持”买入“评级】申万宏源研究指出，百济神州(688235.SH)2025年Q1实现收入80.48 亿元，同比+50.2%，产品收入为79.85亿元，同比+49.9%，实现归母净利润-0.95 亿元，上年同期为-19.08亿元，亏损大幅收窄，若按照美国公认会计原则（GAAP），公司首次实现季度盈利，业绩符合预期。产品收入的增长主要得益于自研产品泽布替尼,以及替雷利珠单抗和安进授权产品的销售增长。根据公司公告，百济神州2025 年全年总收入指引仍为49 亿至53 亿美元，强劲增长的预期受益于泽布替尼在美国的领先地位以及在欧洲和全球其他重要市场的持续扩张。公司是市场上稀缺的同时具有全球化研发和销售能力的创新药公司，核心产品持续放量，公司开始进入盈利拐点，维持”买入“评级。","url":"https://stock-news.laohu8.com/highlight/detail?id=2535300273","media":"金融界","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535300273?lang=zh_cn&edition=fundamental","pubTime":"2025-05-16 14:20","pubTimestamp":1747376412,"startTime":"0","endTime":"0","summary":"申万宏源研究指出，百济神州2025年Q1实现收入80.48 亿元，同比+50.2%，产品收入为79.85亿元，同比+49.9%，实现归母净利润-0.95 亿元，上年同期为-19.08亿元，亏损大幅收窄，若按照美国公认会计原则，公司首次实现季度盈利，业绩符合预期。根据公司公告，百济神州2025 年全年总收入指引仍为49 亿至53 亿美元，强劲增长的预期受益于泽布替尼在美国的领先地位以及在欧洲和全球其他重要市场的持续扩张。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate","earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/05/16142050441828.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["688235","06160","000166","ONC","06978","159992","AMGN"],"gpt_icon":0},{"id":"2535335010","title":"百济神州午前涨逾3% 首季度业绩符合市场预期","url":"https://stock-news.laohu8.com/highlight/detail?id=2535335010","media":"新浪港股","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535335010?lang=zh_cn&edition=fundamental","pubTime":"2025-05-16 11:56","pubTimestamp":1747367760,"startTime":"0","endTime":"0","summary":"　　百济神州午前股价上涨2.85%，现报137.30港元，成交额3.31亿港元。根据公司公告，百济神州2025年全年总收入指引仍为49亿至53亿美元，强劲增长的预期受益于泽布替尼在美国的领先地位以及在欧洲和全球其他重要市场的持续扩张。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2025-05-16/doc-inewtpfc8668040.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4526","BK1588","LU0588546209.SGD","BK1500","LU1969619763.USD","ONC","06160","BK0239","BK1583","LU2328871848.SGD","BK4139","688235","LU0307460666.USD","BK1161"],"gpt_icon":0},{"id":"2535333796","title":"港股异动 | 百济神州(06160)午前涨超3% 首季度业绩符合市场预期 主要产品在美市场份额持续提升","url":"https://stock-news.laohu8.com/highlight/detail?id=2535333796","media":"智通财经","labels":["dataReport","movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535333796?lang=zh_cn&edition=fundamental","pubTime":"2025-05-16 11:36","pubTimestamp":1747366567,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，百济神州午前涨超3%，截至发稿，涨2.85%，报0.7港元，成交额3313.19万港元。根据公司公告，百济神州2025年全年总收入指引仍为49亿至53亿美元，强劲增长的预期受益于泽布替尼在美国的领先地位以及在欧洲和全球其他重要市场的持续扩张。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1293968.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0307460666.USD","688235","ONC","BK4139","06160","BK1161","LU2328871848.SGD","BK1588","LU1969619763.USD","LU0588546209.SGD","BK0239","BK4526","BK1583","BK1500"],"gpt_icon":0},{"id":"2535335180","title":"百济神州启动BGB-16673 vs Pirtobrutinib头对头III期研究","url":"https://stock-news.laohu8.com/highlight/detail?id=2535335180","media":"医药魔方","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535335180?lang=zh_cn&edition=fundamental","pubTime":"2025-05-16 11:27","pubTimestamp":1747366029,"startTime":"0","endTime":"0","summary":"5月15日，全球临床试验收录网站显示，百济神州启动了BGB-16673头对头Pirtobrutinib的III期临床试验。来源：百济神州JPM 2025大会PPT此次启动的头对头研究旨在评估BGB-16673对比Pirtobrutinib治疗既往接受过共价BTK抑制剂治疗的复发或难治性（R/R）慢性淋巴细胞白血病或小淋巴细胞淋巴瘤患者的疗效和安全性。在ASH 2024年会上，百济神州披露了BGB-16673治疗CLL的I期CaDAnCe-101研究数据。BGB-16673在其它恶性血液疾病患者中也有不错的疗效。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250516113513a4805d6d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250516113513a4805d6d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1583","ONC","LU0588546209.SGD","688235","06160","BK1500","LU1969619763.USD","LU0307460666.USD","BK1161","LU2328871848.SGD","BK1588"],"gpt_icon":0},{"id":"2535870813","title":"港股生物医药股走高 百济神州减亏诺诚健华首季盈利","url":"https://stock-news.laohu8.com/highlight/detail?id=2535870813","media":"iDoNews","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535870813?lang=zh_cn&edition=fundamental","pubTime":"2025-05-16 10:28","pubTimestamp":1747362482,"startTime":"0","endTime":"0","summary":"5月16日，港股生物医药板块早盘震荡走高。百济神州一季度营收80.48亿元，同比增长50.2%，归母净亏损收窄至9450.3万元。诺诚健华实现营业收入3.81亿元，同比增长129.92%，归母净利润0.18亿元，首次实现一季度盈利。再鼎医药、科伦博泰生物等涨幅超2%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025051610323494f881dc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025051610323494f881dc&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ONC","BK4139","09969","YANG","BK4614","06160","BK4526"],"gpt_icon":0},{"id":"2535487393","title":"百济神州2025财年第一财季实现净利润1.27百万美元，同比增加100.51%","url":"https://stock-news.laohu8.com/highlight/detail?id=2535487393","media":"市场透视","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535487393?lang=zh_cn&edition=fundamental","pubTime":"2025-05-16 00:00","pubTimestamp":1747324831,"startTime":"0","endTime":"0","summary":"5月16日，百济神州公布财报，公告显示公司2025财年第一财季净利润为1.27百万美元，同比增加100.51%；其中营业收入为11.17亿美元，同比增加48.54%，每股基本收益为0.01美元。机构评级：截至2025年5月16日，当前有30家机构对百济神州目标价做出预测，其中目标均价为334.87美元，其中最低目标价为259.00美元，最高目标价为486.31美元。百济神州有自己的团队进行全球临床试验。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250516000039a47fc86f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250516000039a47fc86f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ONC","688235"],"gpt_icon":0},{"id":"2535187360","title":"高瓴不再是百济神州5%以上持股股东 新“医药一哥”被减持背后：下一个重磅产品待寻","url":"https://stock-news.laohu8.com/highlight/detail?id=2535187360","media":"每日经济新闻","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535187360?lang=zh_cn&edition=fundamental","pubTime":"2025-05-15 23:52","pubTimestamp":1747324321,"startTime":"0","endTime":"0","summary":"此前，百济神州的A股市值一度超过恒瑞医药，被视作A股新“医药一哥”。截至目前，百济神州仍然是国内唯一一家实现了“美股+H股+A股”三地上市的企业。高瓴资本对百济神州的减持从2023年开始，在2024年下半年起减持速度明显加快。这意味着，高瓴在7个多月的时间内减持比例高达5.42个百分点，卖掉了一半以上的持股。但出乎意料的是，特朗普又在5月12日签署了“药品降价”行政令。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025051523521994f81289&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025051523521994f81289&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0307460666.USD","ONC","BK1583","06160","LU2328871848.SGD","LU0588546209.SGD","BK1515","688235","BK1588","09939","BK1161","LU1969619763.USD","BK1500","BK1574"],"gpt_icon":0},{"id":"2535898214","title":"高瓴资本减持百济神州套现36.8亿美元 转投恒瑞医药港股IPO","url":"https://stock-news.laohu8.com/highlight/detail?id=2535898214","media":"市场资讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535898214?lang=zh_cn&edition=fundamental","pubTime":"2025-05-15 12:54","pubTimestamp":1747284840,"startTime":"0","endTime":"0","summary":"观点网讯：5月15日，高瓴资本再度减持百济神州美股股份。此次减持后，其持股比例降至4.89%，不再是持股5%以上股东。按5月9日最低价算，套现资金达36.8亿美元。\n　　据悉，高瓴资本此前已多次减持百济神州，累计套现超110亿港元。此次减持规模为1600万股，从6.03%降至4.89%。减持后，高瓴资本计划认购恒瑞医药港股IPO。\n　　5月15日，恒瑞医药启动H股全球公开发售，计划发行2.25亿股，发行价区间41.45港元至44.05港元。若全额行使相关权利，最高募资额可达130.8亿港元。\n\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：王若云","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/estate/integration/2025-05-15/doc-inewrkfy5156569.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU0345775950.USD","LU1023057109.AUD","BK1588","LU0164880469.USD","BK1161","LU1282649067.USD","IE0032431581.USD","LU1044874839.SGD","BK1142","BK1615","LU1282651048.USD","LU1303224171.USD","LU2328871848.SGD","LU0708995583.HKD","LU0140636845.USD","LU0320764755.SGD","LU0499858602.USD","HSTECH","LU0052750758.USD","YANG","LU0163747925.USD","LU1770034418.SGD","LU0228367735.SGD","LU0314109678.HKD","ONC","LU0588545490.SGD","89618","06160","600276","LU0672654166.SGD","IE00B29SXG58.USD","BK4526","LU0456846285.SGD","BK1249","HSCEI","01276","LU1282649810.SGD","LU0228659784.USD","LU0456827905.SGD","LU2242644610.SGD","LU0051755006.USD","LU0345776255.USD","LU0469268626.HKD","LU0315178854.USD","688235","BK0012","BK1610"],"gpt_icon":0},{"id":"2535629850","title":"高瓴减持百济神州，业内人士：基金到期，LP有分配的需求，系正常退出","url":"https://stock-news.laohu8.com/highlight/detail?id=2535629850","media":"21世纪经济报道","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535629850?lang=zh_cn&edition=fundamental","pubTime":"2025-05-15 12:52","pubTimestamp":1747284720,"startTime":"0","endTime":"0","summary":"有业内人士对南财快讯记者表示，基金投资期一般不超过10年，高瓴此番减持主要是投资百济神州时间超10年，目前基金到期，LP有分配的需求，这是基金正常退出。此外，记者还就减持一事采访百济神州，截至发稿，对方暂未回复。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025051512591694f789ca&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025051512591694f789ca&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ONC","BK4526","BK4139"],"gpt_icon":0},{"id":"2535520928","title":"高瓴减持百济神州，业内人士：基金到期，LP有分配的需求，系正常退出","url":"https://stock-news.laohu8.com/highlight/detail?id=2535520928","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535520928?lang=zh_cn&edition=fundamental","pubTime":"2025-05-15 12:43","pubTimestamp":1747284190,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["LU0307460666.USD","688235","ONC","BK4139","06160","BK1161","LU2328871848.SGD","BK1588","LU1969619763.USD","LU0588546209.SGD","BK0239","BK4526","BK1583","BK1500"],"gpt_icon":0},{"id":"2535852857","title":"高瓴减持百济神州，持股比例降至5%以下！业内人士：基金到期，LP有分配的需求，系正常退出","url":"https://stock-news.laohu8.com/highlight/detail?id=2535852857","media":"南方财经网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535852857?lang=zh_cn&edition=fundamental","pubTime":"2025-05-15 12:36","pubTimestamp":1747283760,"startTime":"0","endTime":"0","summary":"截至去年9月30日，该机构持股为10.31%。这意味着7个多月的时间，高瓴卖掉了一半以上的持股。有业内人士对南财快讯记者表示，基金投资期一般不超过10年，高瓴此番减持主要是投资百济神州时间超10年，目前基金到期，LP有分配的需求，这是基金正常退出。此外，记者还就减持一事采访百济神州，截至发稿，对方暂未回复。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025051512391194f785d7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025051512391194f785d7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ONC","BK4139","BK4526","06160"],"gpt_icon":0},{"id":"2535857604","title":"高瓴抛售百济神州套现至少37亿美元 要去认购恒瑞医药新股","url":"https://stock-news.laohu8.com/highlight/detail?id=2535857604","media":"第一财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535857604?lang=zh_cn&edition=fundamental","pubTime":"2025-05-15 12:25","pubTimestamp":1747283153,"startTime":"0","endTime":"0","summary":"【高瓴抛售百济神州套现至少37亿美元 要去认购恒瑞医药新股】记者注意到，这次减持了百济神州股份后，高瓴资本转头要去认购恒瑞医药（600276.SH）港股IPO了。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"eastmoney_highlight","url":"http://finance.eastmoney.com/news/11158,202505153405425431.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/news/11158,202505153405425431.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"eastmoney_highlight","symbols":["LU2488822045.USD","BK0239","LU1064130708.USD","BK4526","688235","LU1064131003.USD","06160","BK0196","BK1583","LU2328871848.SGD","BK0060","LU1969619763.USD","BK1500","BK0028","LU2148510915.USD","ONC","LU0588546209.SGD","LU0405327148.USD","LU0405327494.USD","BK1588","01276","600276","LU0307460666.USD","BK0188","BK4139","LU1328615791.USD","BK1161","BK0012","BK0183"],"gpt_icon":0},{"id":"2535736869","title":"百济神州将在2025年欧洲血液学协会年会展示血液学产品组合新数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2535736869","media":"百济神州","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535736869?lang=zh_cn&edition=fundamental","pubTime":"2025-05-15 12:04","pubTimestamp":1747281858,"startTime":"0","endTime":"0","summary":"31篇摘要的数据展现出百济神州坚定致力于改变B细胞恶性肿瘤治疗现状四场口头报告重点介绍在研BTK蛋白降解剂BGB-16673和BCL2抑制剂索托克拉用于治疗多种B细胞恶性肿瘤的最新数据美国加州圣卡洛斯——百济神州有限公司是一家全球肿瘤治疗创新公司，今日宣布将于6月12日至15日在意大利米兰举行的欧洲血液学协会年会上展示多种血液恶性肿瘤治疗相关数据。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250515141031a47f25fd&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250515141031a47f25fd&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688235","ONC","BK4139","06160","BK4526"],"gpt_icon":0},{"id":"2535754853","title":"百济神州5月14日成交额为5821.09万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2535754853","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535754853?lang=zh_cn&edition=fundamental","pubTime":"2025-05-15 10:51","pubTimestamp":1747277475,"startTime":"0","endTime":"0","summary":"美东时间2025年5月14日，百济神州成交额为5821.09万美元，成交额较昨日减少32.92%，当日成交量为26.28万股。百济神州于2025年5月14日跌2.13%，报219.95美元，该股过去5个交易日跌5.3%，年初至今涨19.08%，过去60日跌7.63%。百济神州有自己的团队进行全球临床试验。截至2023年，百济神州的核心药物是百悦泽，这是一种治疗各种血癌的小分子药物，占百济神州收入的50%以上。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250515105120a6dfbd80&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250515105120a6dfbd80&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4526","BK4139","ONC"],"gpt_icon":0},{"id":"2535853824","title":"中金：维持百济神州“跑赢行业”评级 目标价198港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2535853824","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535853824?lang=zh_cn&edition=fundamental","pubTime":"2025-05-15 10:49","pubTimestamp":1747277340,"startTime":"0","endTime":"0","summary":"　　中金发布研报称，维持百济神州2025年和2026年盈利预测不变，维持“跑赢行业”评级，基于DCF模型，该行维持A/H/US股目标价280元/198港币/332美元。　　公司公布1Q25业绩：收入11.17亿美元，同比增长49%，其中产品收入11.09亿美元，同比增长48%，GAAP净利润127万美元，收入符合该行预期，扭亏进度超该行预期，主因收入增速明显高于运营费用增长。据公司公告，1Q25泽布替尼美国需求量同比增长54%，这与泽布替尼的实际销售额相匹配。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/hkgg/2025-05-15/doc-inewrcxy8466877.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["ONC","688235","06160"],"gpt_icon":0},{"id":"2535830112","title":"中金：维持百济神州(06160)“跑赢行业”评级 目标价198港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2535830112","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535830112?lang=zh_cn&edition=fundamental","pubTime":"2025-05-15 10:27","pubTimestamp":1747276021,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，中金发布研报称，维持百济神州 2025年和2026年盈利预测不变，维持“跑赢行业”评级，基于DCF模型，该行维持A/H/US股目标价280元/198港币/332美元。据公司公告，1Q25泽布替尼美国需求量同比增长54%，这与泽布替尼的实际销售额相匹配。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1293413.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06160","688235","ONC"],"gpt_icon":0},{"id":"2535886021","title":"百济神州2025年一季报简析：营收上升亏损收窄，盈利能力上升","url":"https://stock-news.laohu8.com/highlight/detail?id=2535886021","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535886021?lang=zh_cn&edition=fundamental","pubTime":"2025-05-15 06:05","pubTimestamp":1747260358,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期百济神州发布2025年一季报。截至本报告期末，公司营业总收入80.48亿元，同比上升50.17%，归母净利润-9450.3万元，同比上升95.05%。本报告期百济神州盈利能力上升，毛利率同比增幅2.74%，净利率同比增幅96.7%。持有百济神州最多的基金为万家行业优选LOF，目前规模为83.09亿元，最新净值1.1626，较上一交易日下跌0.21%，近一年上涨58.28%。第一项试验将匹妥布替尼与化疗免疫疗法进行对比。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250515060834a6df790e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250515060834a6df790e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ONC"],"gpt_icon":0},{"id":"2535243074","title":"高瓴减持！","url":"https://stock-news.laohu8.com/highlight/detail?id=2535243074","media":"中国基金报","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535243074?lang=zh_cn&edition=fundamental","pubTime":"2025-05-14 23:40","pubTimestamp":1747237200,"startTime":"0","endTime":"0","summary":"完成上述减持后，高瓴持有的百济神州H股股份数量从1.25亿股减少至9280.57万股，持股比例从8.97%减少至6.66%。此外，去年12月初，高瓴减仓1784.25万股百济神州，高瓴从百济神州的第二大股东降为第三大股东，不过彼时仍持有9.03%的股份。2023年6月8日至2024年12月2日期间，高瓴曾通过集中竞价和大宗交易方式合计减持百济神州境外流通股股份2199.73万股。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025051423421297599e91&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025051423421297599e91&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06160","ONC","BK4526","BK4139","688235"],"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":4,"totalSize":200,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ONC\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-05-07","symbol":"ONC","fiscalQuarterEnding":"2025/03","expectedEps":-0.71,"name":null,"time":"盘前","type":"earning","dateTimestamp":1746590400000,"reportTimeType":"pre","actualEps":1.22},{"market":"US","date":"2025-02-27","symbol":"ONC","fiscalQuarterEnding":"2024/12","expectedEps":-0.88,"name":null,"time":"盘前","type":"earning","dateTimestamp":1740632400000,"reportTimeType":"pre","actualEps":-1.43},{"market":"US","date":"2024-11-12","symbol":"ONC","fiscalQuarterEnding":"2024/09","expectedEps":-0.88,"name":null,"time":"盘前","type":"earning","dateTimestamp":1731387600000,"reportTimeType":"pre","actualEps":-1.15},{"market":"US","date":"2024-08-07","symbol":"ONC","fiscalQuarterEnding":"2024/06","expectedEps":-2.1,"name":null,"time":"盘前","type":"earning","dateTimestamp":1723003200000,"reportTimeType":"pre","actualEps":-1.15},{"market":"US","date":"2024-05-11","symbol":"ONC","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"盘后","type":"earning","dateTimestamp":1715400000000,"reportTimeType":"post","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ONC\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ONC\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/ONC\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"ONC","date":"2025-06-10","current":-85.639801,"percent":0,"low":-85.639801,"twenty":-43.937121,"median":-38.160199,"eighty":-22.864395,"high":-19.234246,"avg":-36.360804,"sd":14.278049,"marketCap":33602146025},"quantilePoints":[{"date":"2024-05-31","current":-19.860847,"twenty":-20.46703,"median":-20.284421,"eighty":-20.042184,"marketCap":15579384952},{"date":"2024-06-07","current":-20.864085,"twenty":-20.930269,"median":-20.558927,"eighty":-20.042184,"marketCap":16366351618},{"date":"2024-06-14","current":-21.694058,"twenty":-21.409839,"median":-20.844737,"eighty":-20.30869,"marketCap":17017405001},{"date":"2024-06-21","current":-20.966373,"twenty":-21.331475,"median":-20.876952,"eighty":-20.46703,"marketCap":16446589390},{"date":"2024-06-28","current":-19.234246,"twenty":-21.331475,"median":-20.825389,"eighty":-19.981739,"marketCap":15087861974},{"date":"2024-07-05","current":-19.83401,"twenty":-21.208618,"median":-20.693442,"eighty":-19.760805,"marketCap":15558333278},{"date":"2024-07-12","current":-20.525989,"twenty":-21.135228,"median":-20.465877,"eighty":-19.641074,"marketCap":16101139655},{"date":"2024-07-19","current":-20.872652,"twenty":-21.016911,"median":-20.525989,"eighty":-19.707798,"marketCap":16373071895},{"date":"2024-07-26","current":-21.924783,"twenty":-21.374239,"median":-20.660298,"eighty":-19.760805,"marketCap":17198391533},{"date":"2024-08-02","current":-22.081827,"twenty":-21.704901,"median":-20.777003,"eighty":-19.839377,"marketCap":17321581561},{"date":"2024-08-09","current":-37.033118,"twenty":-22.009534,"median":-20.868368,"eighty":-19.874904,"marketCap":19394058972},{"date":"2024-08-16","current":-39.443432,"twenty":-22.36867,"median":-20.966373,"eighty":-19.937065,"marketCap":20656328240},{"date":"2024-08-23","current":-39.274234,"twenty":-33.284244,"median":-21.171036,"eighty":-20.00126,"marketCap":20567720015},{"date":"2024-08-30","current":-38.860864,"twenty":-37.912544,"median":-21.248991,"eighty":-20.190606,"marketCap":20351240040},{"date":"2024-09-06","current":-38.812817,"twenty":-38.506257,"median":-21.456019,"eighty":-20.300725,"marketCap":20326078245},{"date":"2024-09-13","current":-40.29759,"twenty":-38.865563,"median":-21.710093,"eighty":-20.355918,"marketCap":21103646159},{"date":"2024-09-20","current":-41.008162,"twenty":-39.353261,"median":-21.954664,"eighty":-20.405766,"marketCap":21475769498},{"date":"2024-09-27","current":-44.343793,"twenty":-39.883427,"median":-22.072098,"eighty":-20.507104,"marketCap":23222622772},{"date":"2024-10-04","current":-49.961787,"twenty":-40.117185,"median":-22.410559,"eighty":-20.525989,"marketCap":26164738255},{"date":"2024-10-11","current":-47.875901,"twenty":-40.317892,"median":-22.855632,"eighty":-20.558927,"marketCap":25072369873},{"date":"2024-10-18","current":-44.402313,"twenty":-41.008162,"median":-37.033118,"eighty":-20.627155,"marketCap":23253269086},{"date":"2024-10-25","current":-43.1532,"twenty":-43.068033,"median":-37.882149,"eighty":-20.693442,"marketCap":22599114920},{"date":"2024-11-01","current":-41.429716,"twenty":-43.148001,"median":-38.271158,"eighty":-20.724275,"marketCap":21696535276},{"date":"2024-11-08","current":-41.685343,"twenty":-43.068033,"median":-38.746669,"eighty":-20.777003,"marketCap":21830405481},{"date":"2024-11-15","current":-24.188369,"twenty":-42.835701,"median":-38.506257,"eighty":-20.825389,"marketCap":20104967290},{"date":"2024-11-22","current":-24.46985,"twenty":-42.494274,"median":-38.062423,"eighty":-20.864085,"marketCap":20240962418},{"date":"2024-11-29","current":-27.613239,"twenty":-42.262623,"median":-37.45966,"eighty":-20.870939,"marketCap":22851200825},{"date":"2024-12-06","current":-26.519964,"twenty":-42.078114,"median":-35.811244,"eighty":-20.886386,"marketCap":21862847938},{"date":"2024-12-13","current":-23.158686,"twenty":-41.984053,"median":-26.690447,"eighty":-20.951062,"marketCap":19077141333},{"date":"2024-12-20","current":-22.876382,"twenty":-41.961072,"median":-26.519964,"eighty":-21.016911,"marketCap":18791641889},{"date":"2024-12-27","current":-23.581122,"twenty":-41.848457,"median":-25.970587,"eighty":-21.108807,"marketCap":19365505627},{"date":"2025-01-03","current":-23.522344,"twenty":-41.738903,"median":-25.015322,"eighty":-21.169159,"marketCap":19262068568},{"date":"2025-01-10","current":-23.039426,"twenty":-41.667895,"median":-24.95255,"eighty":-21.188412,"marketCap":18831625271},{"date":"2025-01-17","current":-27.361812,"twenty":-41.564427,"median":-24.990614,"eighty":-21.226086,"marketCap":22387798297},{"date":"2025-01-24","current":-28.60727,"twenty":-41.429716,"median":-25.817461,"eighty":-21.248991,"marketCap":23666613889},{"date":"2025-01-31","current":-29.006926,"twenty":-41.129457,"median":-26.292693,"eighty":-21.405551,"marketCap":23976726670},{"date":"2025-02-07","current":-29.003485,"twenty":-41.095232,"median":-26.532547,"eighty":-21.456019,"marketCap":23849552911},{"date":"2025-02-14","current":-29.812673,"twenty":-41.008162,"median":-26.754345,"eighty":-21.694058,"marketCap":24634934161},{"date":"2025-02-21","current":-32.964646,"twenty":-40.974605,"median":-27.361812,"eighty":-21.704901,"marketCap":27250381776},{"date":"2025-02-28","current":-45.085214,"twenty":-41.025576,"median":-28.423545,"eighty":-21.711581,"marketCap":29070314911},{"date":"2025-03-07","current":-41.087466,"twenty":-41.189509,"median":-28.729221,"eighty":-21.882341,"marketCap":26492622821},{"date":"2025-03-14","current":-43.209977,"twenty":-41.608729,"median":-28.790129,"eighty":-21.948688,"marketCap":27861188167},{"date":"2025-03-21","current":-42.024306,"twenty":-41.961072,"median":-29.003485,"eighty":-22.009534,"marketCap":27096684166},{"date":"2025-03-28","current":-44.59433,"twenty":-42.028738,"median":-29.052749,"eighty":-22.054545,"marketCap":28753799426},{"date":"2025-04-04","current":-39.846019,"twenty":-42.270172,"median":-29.231496,"eighty":-22.077935,"marketCap":25692155286},{"date":"2025-04-11","current":-38.484462,"twenty":-42.209323,"median":-29.379987,"eighty":-22.177258,"marketCap":24814242135},{"date":"2025-04-17","current":-38.603,"twenty":-42.109763,"median":-29.75631,"eighty":-22.326782,"marketCap":24890673891},{"date":"2025-04-25","current":-40.929408,"twenty":-42.213935,"median":-30.85745,"eighty":-22.4234,"marketCap":26390709308},{"date":"2025-05-02","current":-42.799955,"twenty":-42.322726,"median":-33.161649,"eighty":-22.493794,"marketCap":27596811853},{"date":"2025-05-09","current":-63.824658,"twenty":-42.611855,"median":-33.528671,"eighty":-22.601969,"marketCap":25042625921},{"date":"2025-05-16","current":-62.94985,"twenty":-42.804476,"median":-34.892623,"eighty":-22.71748,"marketCap":24699380815},{"date":"2025-05-23","current":-72.041871,"twenty":-43.150081,"median":-36.84391,"eighty":-22.787779,"marketCap":28266780880},{"date":"2025-05-30","current":-74.527648,"twenty":-43.429182,"median":-37.087829,"eighty":-22.808465,"marketCap":29242115209},{"date":"2025-06-06","current":-77.688492,"twenty":-43.794804,"median":-38.030583,"eighty":-22.84042,"marketCap":30482322820},{"date":"2025-06-10","current":-85.639801,"twenty":-43.937121,"median":-38.160199,"eighty":-22.864395,"marketCap":33602146025}],"updateTime":1749656283037}}}